The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Unmet needs in multiple myeloma: patients who are refractory to T-cell engagers and CAR-Ts
Enrique Ocio, MD, PhD, Marquis of Valdecilla University Hospital, Santander, Spain, comments on the major unmet needs for patients with multiple myeloma, noting that the medical need has shifted from triple-class refractory patients to those who are refractory to T-cell engagers and CAR-Ts. He emphasizes the importance of optimizing the sequencing of agents to achieve the best bridging therapy for these patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
So the relapsed population now is changing a lot. Some years ago, even some months ago, I would say, maybe some years, we had a triple-class refractory as an admitted medical need. Now we have many different options for these patients. In fact, well, we have approved now several bispecifics, anti-BCMA, anti-GPRC5D. We also have the CAR-Ts. We have some other mechanisms of action. So probably now the medical needs have changed in this situation, And these are those patients that are, I would say, the four-class refractory that are also refractory to these T-cell engagers or the CAR-Ts...
So the relapsed population now is changing a lot. Some years ago, even some months ago, I would say, maybe some years, we had a triple-class refractory as an admitted medical need. Now we have many different options for these patients. In fact, well, we have approved now several bispecifics, anti-BCMA, anti-GPRC5D. We also have the CAR-Ts. We have some other mechanisms of action. So probably now the medical needs have changed in this situation, And these are those patients that are, I would say, the four-class refractory that are also refractory to these T-cell engagers or the CAR-Ts. And in fact, this is what we need now. What we are working on doing that is to know how we can sequence this data and we can use a bispecific followed by a CAR-T or the other way around. We can rescue what is the best bridging therapy we can do for these patients. But I think we have moved this patient, the unmet medical need, to one line later, which is those patients that have already received the T-cell redirecting therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Bristol-Myers Squibb: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Regeneron: Honoraria; GSK: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Menarini: Consultancy, Honoraria; Oncopeptides: Consultancy, Honoraria; Johnson & Johnson – Janssen: Consultancy, Honoraria, Speakers Bureau; Takeda: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Amgen: Consultancy, Honoraria.
